Industria
PCAS: 2017 Annual Results
, specialists in the development and generation of complex molecules for life sciences and innovative technologies, publishes its annual income statement for 2017.
At December 31, 2017, consolidated for the PCAS Group totaled
, up 13.7% compared to the same period for the previous year.
totaled , against €27.3 million in 2016, a margin of against 14.2% in 2016. The Group's totaled , against €16.2 million in 2016, boosted by the growth in Group activities.
The totaled in 2017, against -€6.4 million in 2016.
PCAS totaled in 2017, against €6.6 million in 2016.
The Group's stood at against €48.7 million at December 31, 2016, affected by an increase in accounts receivable due to a sharp rise in sales at the end of 2017, and to a lesser extent by higher inventory levels than at the end of the previous year.
In 2018 the Group's net sales are expected to show modest growth. The Group's net income could however be significantly affected if the current euro-dollar rate were to be confirmed.
Given an ambitious investment program to support the business growth, the Board of Directors will ask the next Annual General Meeting not to approve payment of a dividend on the earnings of 2017.
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.
www.pcas.com
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti